These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 2730266)

  • 1. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide.
    Barakat S; Melmed S
    Arch Intern Med; 1989 Jun; 149(6):1443-5. PubMed ID: 2730266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U; Quabbe HJ
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical management of acromegaly: effects of SMS 201-995 in 30 patients.
    Pagani G; Montini M; Gianola D; Pagani MD; Tengattini F; Dominoni P; Ghilardi G; Cortesi L; Pedroncelli A; Tonnarelli GP
    Endocrinol Exp; 1990 Mar; 24(1-2):175-85. PubMed ID: 2361459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin analogs in the treatment of acromegaly.
    Lamberts SW; Reubi JC; Krenning EP
    Endocrinol Metab Clin North Am; 1992 Sep; 21(3):737-52. PubMed ID: 1355729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F; Magony S; Julesz J
    Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Experience in treating acromegalic patients with long-acting octreotide].
    Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
    Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
    Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octreotide in the management of active acromegaly due to inoperable growth hormone-secreting adenoma.
    Candrina R
    Recenti Prog Med; 1994 Jan; 85(1):13-9. PubMed ID: 8184174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery.
    Lucas-Morante T; García-Uría J; Estrada J; Saucedo G; Cabello A; Alcañiz J; Barceló B
    J Neurosurg; 1994 Jul; 81(1):10-4. PubMed ID: 8207509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.
    Kurahashi K; Endo I; Kondo T; Morimoto K; Yoshida S; Kuroda A; Aihara KI; Matsuhisa M; Nakajima K; Mizobuchi Y; Nagahiro S; Abe M; Fukumoto S
    Intern Med; 2017 Sep; 56(18):2455-2461. PubMed ID: 28824054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly.
    Gradiser M; Matovinovic M; Vrkljan M
    Croat Med J; 2007 Feb; 48(1):87-91. PubMed ID: 17309144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of octreotide acetate on thyrotropin-secreting adenoma: report of two cases and review of the literature.
    Yoenem A; Cakyr B; Azal O; Corakcy A; Kutlu M; Oezata M
    Endocr Regul; 1999 Dec; 33(4):169-74. PubMed ID: 10700085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical management of acromegaly--what and when?
    Melmed S
    Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():13-7. PubMed ID: 8372605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presurgical octreotide treatment in acromegaly.
    Stevenaert A; Beckers A
    Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():18-20. PubMed ID: 8372606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary octreotide LAR therapy in GH-secreting pituitary adenoma.
    Harinarayan CV
    J Indian Med Assoc; 2004 May; 102(5):258, 260-1. PubMed ID: 15636029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of prolactinomas and growth hormone-producing adenomas with an injectable bromocriptine retard preparation and a somatostatin analogue delivered by an implantable pump.
    Schatz H; Stracke H; Hildebrandt G
    Pathol Res Pract; 1988 Sep; 183(5):546-51. PubMed ID: 3237541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.
    Cozzi R; Montini M; Attanasio R; Albizzi M; Lasio G; Lodrini S; Doneda P; Cortesi L; Pagani G
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1397-403. PubMed ID: 16449332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.